171 results
Page 4 of 9
424B3
053xxw6o3p2dchovp1zs
19 Jan 22
Prospectus supplement
4:05pm
8-K
EX-10.1
ygkx6j
4 Jan 22
Entry into a Material Definitive Agreement
6:02am
8-K
EX-99.1
y8g6loj oka
4 Jan 22
Entry into a Material Definitive Agreement
6:02am
8-K
EX-99.1
86c0bwf20ufxy8g
12 Nov 21
7 of 16 (44%) patients achieved best overall response of partial response
7:06am
8-K
pseu22a
12 Nov 21
7 of 16 (44%) patients achieved best overall response of partial response
7:06am
8-K
EX-99.1
qjxs1edz ci
9 Nov 21
3 of 5 (60%) patients achieved a partial response All 5 patients treated demonstrated tumor decrease from baseline
8:29am
8-K
v8ov1sq rpv3uh0e
9 Nov 21
3 of 5 (60%) patients achieved a partial response All 5 patients treated demonstrated tumor decrease from baseline
8:29am
8-K
EX-99.1
eshks
28 Oct 21
Aravive Reports Third Quarter 2021 Financial Results and Provides Corporate Updates
4:06pm
8-K
a4c8avveps648p0gq
9 Aug 21
Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 for the Treatment of Pancreatic Adenocarcinoma
7:09am
8-K
EX-99.1
batva 3ajd
9 Aug 21
Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 for the Treatment of Pancreatic Adenocarcinoma
7:09am
8-K
EX-99.1
ezbk0ijtq26b0 sv
5 Aug 21
Aravive Reports Second Quarter 2021 Financial Results and Provides Corporate Updates
7:06am
8-K
9z33r
15 Jul 21
Aravive Achieves Second Development Milestone from 3D Medicines
7:05am
8-K
EX-99.1
4r9 wxtf7yho9hg
15 Jul 21
Aravive Achieves Second Development Milestone from 3D Medicines
7:05am
8-K
o73qva7o5b
24 Jun 21
Regulation FD Disclosure
7:07am
8-K
EX-99.1
7f91dpd8cfw
24 Jun 21
Regulation FD Disclosure
7:07am
8-K
EX-10.1
3fr 7e51pge2ycg
14 Jun 21
Entry into a Material Definitive Agreement
4:08pm
8-K
EX-99.1
249smi39l2unr
18 May 21
Aravive Announces Three New Appointments to its Board of Directors
7:05am